Literature DB >> 32893093

The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer.

Stephanie L Goff1, David N Danforth2.   

Abstract

Immune cells are present in normal breast tissue and in breast carcinoma. The nature and distribution of the immune cell subtypes in these tissues are reviewed to promote a better understanding of their important role in breast cancer prevention and treatment. We conducted a review of the literature to define the type, location, distribution, and role of immune cells in normal breast tissue and in in situ and invasive breast cancer. Immune cells in normal breast tissue are located predominantly within the epithelial component in breast ductal lobules. Immune cell subtypes representing innate immunity (NK, CD68+, and CD11c+ cells) and adaptive immunity (most commonly CD8+, but CD4+ and CD20+ as well) are present; CD8+ cells are the most common subtype and are primarily effector memory cells. Immune cells may recognize neoantigens and endogenous and exogenous ligands and may serve in chronic inflammation and immunosurveillance. Progression to breast cancer is characterized by increased immune cell infiltrates in tumor parenchyma and stroma, including CD4+ and CD8+ granzyme B+ cytotoxic T cells, B cells, macrophages and dendritic cells. Tumor-infiltrating lymphocytes in breast cancer may serve as prognostic indicators for response to chemotherapy and for survival. Experimental strategies of adoptive transfer of breast tumor-infiltrating lymphocyte may allow regression of metastatic breast cancer and encourage development of innovative T-cell strategies for the immunotherapy of breast cancer. In conclusion, immune cells in breast tissues play an important role throughout breast carcinogenesis. An understanding of these roles has important implications for the prevention and the treatment of breast cancer. Published by Elsevier Inc.

Entities:  

Keywords:  Breast ductal cells; Immunology; Intraepithelial lymphocytes; Tumor immunology; Tumor-infiltrating lymphocytes

Mesh:

Year:  2020        PMID: 32893093      PMCID: PMC7775885          DOI: 10.1016/j.clbc.2020.06.011

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  26 in total

Review 1.  Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.

Authors:  Mitra Behroozaghdam; Maryam Dehghani; Amirhossein Zabolian; Davood Kamali; Salar Javanshir; Farzaneh Hasani Sadi; Mehrdad Hashemi; Teimour Tabari; Mohsen Rashidi; Sepideh Mirzaei; Atefeh Zarepour; Ali Zarrabi; Danielle De Greef; Anupam Bishayee
Journal:  Cell Mol Life Sci       Date:  2022-10-04       Impact factor: 9.207

2.  Breast Cancer Prognosis Prediction and Immune Pathway Molecular Analysis Based on Mitochondria-Related Genes.

Authors:  Weixu Luo; Yuanshan Han; Xin Li; Zhuo Liu; Pan Meng; Yuhong Wang
Journal:  Genet Res (Camb)       Date:  2022-05-31       Impact factor: 1.375

Review 3.  Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment.

Authors:  Rosalia Busà; Matteo Bulati; Ester Badami; Giovanni Zito; Daniela Claudia Maresca; Pier Giulio Conaldi; Giuseppe Ercolano; Angela Ianaro
Journal:  Front Cell Dev Biol       Date:  2022-05-26

4.  Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.

Authors:  Kevin J Thompson; Roberto A Leon-Ferre; Jason P Sinnwell; David M Zahrieh; Vera J Suman; Filho Otto Metzger; Sarah Asad; Daniel G Stover; Lisa Carey; William M Sikov; James N Ingle; Minetta C Liu; Jodi M Carter; Eric W Klee; Richard M Weinshilboum; Judy C Boughey; Liewei Wang; Fergus J Couch; Matthew P Goetz; Krishna R Kalari
Journal:  NAR Cancer       Date:  2022-06-17

5.  Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.

Authors:  Jennifer R Bourn; Sasha J Ruiz-Torres; Brian G Hunt; Nancy M Benight; Susan E Waltz
Journal:  Cancer Lett       Date:  2021-01-27       Impact factor: 8.679

6.  Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.

Authors:  Nikolaos Zacharakis; Lutfi M Huq; Samantha J Seitter; Sanghyun P Kim; Jared J Gartner; Sivasish Sindiri; Victoria K Hill; Yong F Li; Biman C Paria; Satyajit Ray; Billel Gasmi; Chyi-Chia Lee; Todd D Prickett; Maria R Parkhurst; Paul F Robbins; Michelle M Langhan; Thomas E Shelton; Anup Y Parikh; Shoshana T Levi; Jonathan M Hernandez; Chuong D Hoang; Richard M Sherry; James C Yang; Steven A Feldman; Stephanie L Goff; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2022-02-01       Impact factor: 50.717

Review 7.  Emerging nanomedicines for effective breast cancer immunotherapy.

Authors:  Amirhossein Bahreyni; Yasir Mohamud; Honglin Luo
Journal:  J Nanobiotechnology       Date:  2020-12-09       Impact factor: 10.435

Review 8.  Cracking the Breast Cancer Glyco-Code through Glycan-Lectin Interactions: Targeting Immunosuppressive Macrophages.

Authors:  Nuno Lopes; Viviana G Correia; Angelina S Palma; Catarina Brito
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 5.923

9.  Integrated Profiling Identifies CCNA2 as a Potential Biomarker of Immunotherapy in Breast Cancer.

Authors:  Yichao Wang; Qianyi Zhong; Zhaoyun Li; Zhu Lin; Hanjun Chen; Pan Wang
Journal:  Onco Targets Ther       Date:  2021-04-09       Impact factor: 4.147

10.  Optimal solution of the fractional order breast cancer competition model.

Authors:  H Hassani; J A Tenreiro Machado; Z Avazzadeh; E Safari; S Mehrabi
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.